Skip to main content
. 2018 Feb 26;46(8):3891–3905. doi: 10.1093/nar/gky128

Figure 1.

Figure 1.

Human CHD1 is required for repair of DSBs through HR. (A) A Western blot shows that CHD1 was successfully knocked out in RPE1 cells by CRISPR-Cas9. Clone 6 was used for subsequent assays. (B) Clonogenic survival assays with WT or CHD1-KO RPE1 cells. The dishes were stained 12 days after IR. (C) Quantification of the clonogenic survival assays shown in (B). Mean and SD of three experiments were shown. **, p < 0.01. (D) Quantification of the DR-GFP (HR) assay in control or CHD1 depleted cells. CtIP knockdown (siCtIP) was used as a positive control. (E) Quantification of the EJ5 (NHEJ) assay. Ligase-IV knockdown (siLigIV) was used as a positive control. Western blots shown below each graph indicate successful knockdown. (F) Sensitivity of CHD1-KO cells and control cells to PARP inhibitor Olaparib (top) and PTEN inhibitor VO-OHpic. Cells were treated with the drugs for 6 days, and cell viability was measured by the CellTiter-Glo Assay.